

**ASX & Media Release**

## **Patrys Completes \$2.85 Million Capital Raising**

**Melbourne, Australia; 10 September, 2012:** Patrys Limited (ASX: PAB; Company), a clinical stage biopharmaceutical company, is pleased to announce the completion of its share purchase plan (SPP).

The funds raised from the SPP combined with the recent placement which was supported by institutions and high net worth individuals (announced on 22 June 2012) bring the total capital raised to approximately \$2.85 million. All shares in the placement and SPP were issued at \$0.02.

Proceeds from the SPP and placement together with existing finances will be used to:

- Complete the PAT-SM6 Phase I/IIa open label multi-dose clinical trial in multiple myeloma
- Further prepare PAT-LM1 for clinical trial
- Support out-licensing activities in respect of PAT-SC1
- Expand the pipeline through internal R&D

Dr. Marie Roskrow, Patrys CEO said: "We are delighted with the strong support we have received from both new and existing shareholders in respect of the placement and SPP."

**-Ends-**

**For further information, please contact:**

*Patrys Limited:*

Marie Roskrow  
Chief Executive Officer  
P: +61 3 9670 3273 or  
[info@patrys.com](mailto:info@patrys.com)

*Patrys Limited:*

Roger McPherson  
Chief Financial Officer  
P: +61 3 9670 3273 or  
[info@patrys.com](mailto:info@patrys.com)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibody therapies for cancer. More information can be found at [www.patrys.com](http://www.patrys.com).